FOXO4-DRI

Overview

FOXO4-DRI is an engineered D-retro-inverso peptide designed to act as a senolytic — a compound that selectively kills senescent ('zombie') cells. It works by disrupting the interaction between the FOXO4 protein and p53, which normally keeps senescent cells alive; freeing p53 triggers apoptosis preferentially in those cells. In the landmark 2017 work and subsequent animal studies, treated aged mice showed improvements such as restored fur density, better kidney-function markers, and increased activity. All efficacy data, however, come from cell and animal experiments — there are no human clinical trials, and it is NOT FDA-approved. Any anti-aging benefit in people is entirely unproven.

Commonly Reported Uses

These are uses commonly discussed or marketed by users and vendors — not a list of proven or approved benefits, and not a recommendation.

• Anti-aging / clearance of senescent cells (marketed claim; animal data only, no human trials)
• Tissue/organ function restoration in aging (preclinical concept; not demonstrated in humans)

What to Track

Data points you and your clinician might monitor. For observation only — not a diagnostic protocol.

• Subjective — daily energy, recovery, and overall well-being check-ins over a baseline period
• WHOOP — recovery score, HRV, and sleep trend as general physiology context
• Labs — only clinician-ordered biomarkers; there is no validated consumer marker of senolysis to track

Sources & References

1. [1]FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice — PubMed